BioCentury
ARTICLE | Clinical News

PX-866: Interim Phase II data

May 28, 2012 7:00 AM UTC

Interim data from 15 evaluable patients with GBM at first recurrence in a 2-stage, single-arm, open-label, Canadian Phase II trial showed that 12 patients discontinued therapy after receiving a median...